* PDS Biotechnology Corp PDSB.OQ PDSB.O is expected
to show no
change in quarterly revenue when it reports results on August
13 for the period ending June 30 2024
*
* LSEG's mean analyst estimate for PDS Biotechnology Corp
is for
a loss of 34 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for PDS
Biotechnology
Corp is $9.00, above its last closing price of $3.05.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.37 -0.37 -0.30 Beat 18.2
Dec. 31 2024 -0.60 -0.44 -0.35 Beat 20.2
Sep. 30 2023 -0.44 -0.45 -0.35 Beat 21.5
Jun. 30 2023 -0.35 -0.35 -0.37 Missed -6.6
Mar. -0.31 -0.31 -0.32 Missed -4.7
31 2023
Dec. 31 2022 -0.29 -0.67 Missed -133.3
Sep. 30 2022 -0.28 -0.28 -0.26 Beat 7.6
Jun. 30 2022 -0.28 -0.28 -0.20 Beat 29
This summary was machine generated August 9 at 18:35 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)